Six patients who were treated with abiraterone had androgen receptor (AR) protein expression that ranged from 40% to 100%, including three patients with breast cancer, one patient with hepatocellular carcinoma, and one patient with bladder cancer (Table 2). Here, AR is linked to breast carcinoma.